SCHEMBL19876244

SCHEMBL19876244

CC(C)(C)c1noc(C(=O)O)n1.NC(=O)c1ccc(-c2ccnc3[nH]c(=O)[nH]c23)c(CO)c1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 19/20 0.49
▸ LCK P06239 1/20 0.36
▸ BRD4 O60885 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19876242 0.82 BTK (0.55) BTKLCK
SCHEMBL19876240 0.80 BTK (0.47) BTKLCKBRD4
SCHEMBL19876266 0.80 BTK (0.56) BTKLCKBRD4KCNH2
SCHEMBL19876271 0.79 BTK (0.57) BTKLCKKCNH2
SCHEMBL19876208 0.76 BTK (0.54) BTKLCKKCNH2
SCHEMBL19876263 0.71 BTK (0.60) BTKLCK
SCHEMBL19876267 0.70 BTK (0.73) BTKLCK
SCHEMBL19876207 0.69 BTK (0.60) BTKLCK
SCHEMBL19876282 0.68 BTK (0.67) BTKLCKKCNH2
SCHEMBL19889780 0.66 BTK (1.00) BTKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3500569-B1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-05-18 — — EP disclosed
CN-109641892-B 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof 默克专利有限公司 2021-07-02 — — CN disclosed
US-10266528-B2 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof MERCK PATENT GMBH (DE) 2019-04-23 — — US disclosed
US-20180051024-A1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2018-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266528-B2 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof BTK, SYK, LCK BTK 1/4885LCK 3/4885BRD4 85/4885
US-20180051024-A1 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF BTK, SYK, LCK BTK 1/4885LCK 3/4885BRD4 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback